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ABSTRACT
The V1V2 region of HIV-1 gp120 harbors a major vulnerable site targeted by a group of broadly neutralizing monoclonal anti-
bodies (MAbs) such as PG9 through strand-strand recognition. However, this epitope region is structurally polymorphic as it
can also form a helical conformation recognized by RV144 vaccine-inducedMAb CH58. This structural polymorphism is a po-
tential mechanism for masking the V1V2 vulnerable site. Designing immunogens that can induce conformation-specific anti-
body (Ab) responses may lead to vaccines targeting this vulnerable site. We designed a panel of immunogens engrafting the
V1V2 domain into trimeric and pentameric scaffolds in structurally constrained conformations. We also fused V1V2 to an Fc
fragment to mimic the unconstrained V1V2 conformation.We tested these V1V2-scaffold proteins for immunogenicity in rab-
bits and assessed the responses by enzyme-linked immunosorbent assay (ELISA) and competition assays. Our V1V2 immuno-
gens induced distinct conformation-specific Ab responses. Abs induced by structurally unconstrained immunogens reacted pref-
erentially with unconstrained V1V2 antigens, suggesting recognition of the helical configuration, while Abs induced by the
structurally constrained immunogens reacted preferentially with constrained V1V2 antigens, suggesting recognition of the
-strand conformation. The Ab responses induced by the structurally constrained immunogens were more broadly reactive and
had higher titers than those induced by the structurally unconstrained immunogens. Our results demonstrate that immunogens
presenting the different structural conformations of the gp120 V1V2 vulnerable site can be designed and that these immunogens
induce distinct Ab responses with epitope conformation specificity. Therefore, these structurally constrained V1V2 immuno-
gens are vaccine prototypes targeting the V1V2 domain of the HIV-1 envelope.
IMPORTANCE
The correlates analysis of theRV144HIV-1 vaccine trial suggested that the presence of antibodies to theV1V2 region ofHIV-1 gp120
was responsible for themodest protection observed in the trial. In addition, V1V2harbors one of the key vulnerable sites ofHIV-1 Env
recognized by a family of broadly neutralizingMAbs such as PG9. Thus, V1V2 is a key target for vaccine development.However, this
vulnerable site is structurally polymorphic, and designing immunogens that present different conformations is crucial for targeting
this site.We showhere that such immunogens can be designed and that they induced conformation-specific antibody responses in
rabbits. Our immunogens are therefore prototypes of vaccine candidates targeting theV1V2 region ofHIV-1 Env.
TheHIV-1 envelope (Env) complex of glycoproteins gp120 andgp41 is the target for neutralizing antibodies (nAbs) induced
in HIV-1-infected patients and for HIV/AIDS vaccine develop-
ment (1, 2). Glycoprotein gp120 has been conventionally divided
into five variable and five conserved regions (3), and the region of
the first and second variable loops (V1V2) is the most diverse
region of Env in both sequence and length (4). However, recent
data have shown that V1V2 can form, in the structurally con-
strained scaffolded V1V2 or the stabilized BG505 SOSIP.664
trimer, a unique five-stranded -barrel structure with strands A,
B, C, C=, and D (5, 6). In the trimer context, the V1V2 domain is
located at the apex of the Env trimer, and the three V1V2 regions
in the trimer join together at the center to form a top layer of the
Env complex (5, 7–9). This layer can shield the coreceptor binding
sites as well as partially occlude the third variable region (V3); it
can also make large movements upon CD4 receptor binding to
expose the coreceptor binding sites (5, 10, 11). V1V2 also harbors
a putative integrin-binding site thatmay alsomediate Env binding
to host cells (12–14). One such site, the tripeptide LD(I/V) motif
at amino acid positions 179 to 181 (HxB2 numbering) (15), is
located at the beginning of the C= strand in the -barrel (6).
The spatial apex location of V1V2 on the Env spike makes it a
natural target for the human immune system. HIV-infected indi-
viduals canmake cross-reactiveV1V2Abs, andmany human anti-
V1V2monoclonal antibodies (MAbs) have been isolated (16–25).
Epitopes for some of these MAbs have been characterized and
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were recently classified into three major types: V2i, V2p, and V2q
(26, 27). The V2i type is defined by a panel of human MAbs,
including 830A, 697-D, and 2158 (17, 26–30). Extensive immu-
nological, mutagenesis, and structural data have shown that the
V2i epitopes overlap the LD(I/V) integrin-binding site, andAbs of
this family recognize discontinuous regions in V1V2 (6, 26–28).
TheV2p type is defined by humanMAbsCH58 andCH59 isolated
from a vaccinee of the phase III RV144 human vaccine trial (23,
31, 32). Monoclonal Abs CH58 and CH59 react with V2 peptides,
indicating that the V2p epitopes are structurally unconstrained
and have a helical or helical-coil structure (23). The V2q type was
defined by quaternary neutralizing epitope MAbs including PG9
and PG16 (19). Crystal structures of PG9 and PG16 in complex
with engineered V1V2 scaffolds have shown that these MAbs rec-
ognize a region in strand C of V1V2, via a strand-strand interac-
tion, as well as two N-linked glycans using the head of the long
complementarity-determining region (CDR) H3 harbored by
these V2qMAbs (33, 34). In the V1V2 scaffolds used to crystallize
these MAbs, the V1V2 from ZM109 or CAP45 [V1V2(ZM109) or
V1V2(CAP45), respectively] is grafted into a -hairpin region in
the protein G B1 domain (Protein Data Bank [PDB] accession
number 1FD6) so that the V1V2 is structurally constrained to
maintain the conformation found in the trimeric apex (5). Al-
though the protein regions of theV2q epitopes overlaps that of the
V2p epitopes, the structures of the former have a -strand con-
formation while those of the latter have a helical conformation.
The V2p MAbs have weak and very restricted neutralizing activi-
ties (23), while the V2q-specific MAbs PG9 and PG16 have been
shown to neutralize greater than 70% of virus strains tested (19).
Thus, the V2q epitope region is a major site of vulnerability on
Env; designing immunogens that can induce Ab responses target-
ing this conformation has not yet been accomplished.
Data from the correlates analysis of the human clinical vaccine
trial RV144, the only human vaccine trial with moderate but sig-
nificant efficacy against HIV-1 acquisition, have demonstrated
that vaccine-induced IgG Abs targeting V1V2 inversely correlated
with the risk of infection (35), and immunologic data delineated
the specificity and cross-reactivity of these Abs (36, 37). The Abs
induced by the vaccine reacted with a murine leukemia virus
(MuLV) V1V2 gp70 fusion protein, a reagent recognized by the
V2i Abs (28). There was no evidence of the elicitation of V2q Abs
by the RV144 vaccine in that little neutralizing activity was de-
tected, and neutralization was not associated with reduced infec-
tion rates (35, 38). A sieve analysis that compared the V1V2 se-
quences of viruses fromplacebo and those from vaccine recipients
identified two positions of immune pressure on the virus in V2,
residues 169 and 181, supporting the hypothesis that V1V2 Abs
correlated with the reduced risk of infection (39). These findings
suggest that V1V2 can serve as an important target for HIV vac-
cine development, but the modest efficacy of RV144 indicates the
need for a more efficacious vaccine.
Designing immunogens targeting various epitopes of V1V2
and dissecting Ab responses targeting the three epitope types in
animal models will help further improve upon current vaccine
candidates. We show here that immunogens presenting various
representations of the V1V2 epitopes can be rationally designed
and that these different immunogens induce distinct Ab responses
targeting the particular defined epitopes within this region. These
results provide a proof of principle that vaccine candidates target-
ing the V1V2 vulnerable sites can be rationally designed.
MATERIALS AND METHODS
Ethics statement. Rabbit experiments were performed according to the
guidelines of the Animal Welfare Act at the University of Massachusetts
Medical School in its animal facility, which is fully accredited by AAALAC
International with a current Animal Welfare Assurance on file. The im-
munization protocol was reviewed and approved by the Institutional An-
imal Care and Use Committees of both the University of Massachusetts
Medical School and the New York University School of Medicine.
Design of trimeric V1V2 scaffolds. Two trimeric V1V2-scaffold im-
munogens, V1V2(ZM53)-2J9C and V1V2(ZM109)-2F5K, based on the
structures of PDB accession numbers 2J9C and 2F5K, respectively, were
designed using the internal coordinatemechanics (ICM)molecularmod-
eling environment (40). We have implemented a pipeline of filters to
screen the PDB (http://www.rcsb.org/pdb/) for scaffolds with desired
structural features. Symmetric homotrimeric structures were extracted
from the PDB. Within each structure, -hairpins (if present) were iden-
tified. Each -hairpin was checked for surface exposure so that a domain
grafted on it could potentially extend into open space without colliding
with the scaffold. For each hairpin, its position and orientation with re-
spect to the 3-fold axis of the trimeric assembly were assessed in terms of
distance from the trimer axis and two angles (Fig. 1).
Target parameters inferred from the approximate reconstruction of
the V1V2 domain position within the trimer were as follows: the center
mass of the residue pair (Ala125 and Gln197) immediately preceding the
disulfide (Cys126 and Cys196) that delimits the V1V2 domain was12 Å
from the trimer axis, and the vector of the -hairpin direction was tilted
20° both outwards and clockwise around the axis (when viewed from
above the trimer apex). Scaffolds that had these three parameters closest to
the target were further evaluated by superimposing N- and C-terminal
strands of the V1V2 domain structure onto corresponding strands of the
scaffold hairpin to create a simple model of the graft-scaffold construct,
which was assessed for clashes between the V1V2 domain and the scaffold
or between the V1V2s themselves. Finally, completemodels were built for
the best candidates and energyminimized, and final scaffold selectionwas
made upon visual inspection of the models.
TTB-based immunogen.A crystal structure of typhoid toxin complex
(PDB accession number 4K6L) was used to identify a disulfide bond at the
C terminus of subunit B that is suitable for insertion of the V1V2 domain
(41). A small loop between residues Cys128 and Cys133 in typhoid toxin
subunit B (TTB) was replaced with V1V2 amino acids between Cys126
and Cys196 of ZM109 gp120. The structure of V1V2 in the PG9 complex
was used tomodel the scaffolded pentamer, which showed that there were
no clashes between the V1V2 regions in the pentamer (Fig. 1D). This
construct is named V1V2(ZM109)-TTB.
Fc-linked immunogens. Two types of Fc-linked immunogens were
constructed based on the available V1V2 scaffolds by linking them with
the rabbit Fc fragment consisting of the heavy chain hinge and the CH2
and CH3 regions. The first type, V1V2(ZM109)-1FD6-Fc, based on the
1FD6-scaffolded V1V2 used in crystallizing V2q MAbs (33, 34), is struc-
turally constrained. The second type, represented by V1V2(1086)-Fc and
V1V2(ZM109)-Fc, based on the V1V2-tags protein (23), is structurally
unconstrained. The rabbit Fc gene was first cloned into the XbaI/BamHI
sites of the mammalian expression vector pVRC8400 (42), and an NheI
site was engineered preceding the rabbit Fc gene, located in a spacer be-
tween the genes of the V1V2 domain or scaffold and Fc. V1V2(ZM109)-
1FD6, V1V2(1086), or V1V2(ZM109) was cloned into the EcoRV/NheI
sites of the modified expression vector pVRC8400.
Production of V1V2 immunogens. Gene constructs were codon op-
timized for mammalian cell expression and synthesized by commercial
vendors with a secretion signal, and, for non-Fc linked constructs, a C-
terminal human rhinovirus (HRV) 3C protease cleavage site, an 8His
tag, and a Strep-Tag II. They were then cloned into the modified expres-
sion vector pVRC8400 (kindly provided by the Vaccine Research Center,
National Institutes of Health) (42). Plasmid DNAs encoding these im-
munogens were transiently transfected intoHEK293SGnTI/ cells (43),
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cultured in Erlenmeyer flasks using 15 to 25%of the nominal volume, and
rotated at 110 to 130 rpm under standard humidified conditions (37°C
and 5% CO2). Cells were allowed to secrete the V1V2 immunogens for
72 h. For V1V2(ZM53)-2J9C, V1V2(ZM53)-2F5K, and V1V2(ZM109)-
TTB, cell supernatants were concentrated, filtered, and loaded onto
Ni-nitrilotriacetic acid (NTA) beads, and proteins were eluted with
600 mM imidazole. For V1V2(ZM109)-1FD6-Fc, V1V2(1086)-Fc, and
V1V2(ZM109)-Fc, cell supernatants were concentrated, filtered, and
loaded onto protein A columns; proteins were eluted with citric acid. The
immunogens were flash frozen and stored at 80°C. The antigenicity of
the V1V2-scaffold proteins was tested by ELISA with various human
monoclonal antibodies.
Chemical conjugation of V1V2(ZM109)-1FD6 and CTB. Purified
cholera toxin subunit B (CTB; Sigma-Aldrich) and V1V2(ZM109)-1FD6
were chemically conjugated using the heterobifunctional cross-linker N-
succinimidyl 3-(2-pyridyldithio) propionate (SPDP; Thermo Scientific).
One milligram of V1V2(ZM109)-1FD6 (2 mg/ml in phosphate-buffered
saline [PBS]) was incubated with SPDP (final concentration, 0.6 mM) for
1 h at room temperature to add pyridyl disulfide groups to the primary
amines of the protein. The reaction mixture was then desalted and buffer
exchanged to PBS by a size exclusion membrane filter to remove excess
reagent and by-products (pyridine 2-thione). Similarly, 1 mg of CTB (2
mg/ml in PBS) was incubated with SPDP (final concentration, 0.6 mM)
for 1 h at room temperature and then desalted and buffer exchanged to
PBS. Pyridyldithiol-activated CTB was then incubated with dithiothreitol
(DTT; 50 mM) for 30 min at room temperature to expose the sulfhydryl
groups and then desalted and buffer exchanged to PBS as before. Finally,
equal amounts of pyridyldithiol-activated V1V2(ZM109)-1FD6 and sul-
fhydryl-activated CTB were mixed, followed by incubation at room tem-
perature overnight for conjugation. The conjugated sample was desalted
as before and purified by size exclusion chromatography, and the endo-
toxin content was measured to confirm that there had been no significant
contamination during the conjugation process.
Immunization of rabbits. Female New ZealandWhite rabbits, 8 to 10
weeks old (with a body weight of 2 kg), were purchased from Harlan
Laboratories (Indianapolis, IN) and housed in the animal facility man-
aged by the Department of Animal Medicine at the University of Massa-
chusetts Medical School in accordance with an IACUC-approved proto-
col. Three to five rabbits were included in each immunization group.
For the priming immunizations, all rabbits received codon-optimized
gp120.ZM109DNA in the pJW4303 vector and were immunized at weeks
0, 2, and 4 using a Bio-Rad Helios gene gun (Bio-Rad Laboratories, Her-
cules, CA). The gp120 DNA vaccine plasmids were applied as a coating
onto 1.0-m gold beads at a ratio of 2 g of DNA per mg of gold. Each
gene gunshot delivered 1 g of DNA to a total of 36 nonoverlapping sites
on the shaved abdominal skin for each DNA immunization. In two of the
groups (H3.4 and H3.5) (see Table 3), the rabbits also received protein
immunogens at the same time as DNA. For the boosting immunizations,
the animals received two doses of either gp120(ZM109) or one of the
V1V2-scaffold immunogens at weeks 10 and 14. For all protein immuni-
FIG 1 Designing of V1V2 immunogens. (A) Geometric parameters of the-hairpin orientation of the V1V2 stem used for scaffold filtering. The 3-fold axis (the
vertical blue line) of the trimer, the distance (R) of the V1V2 stem from the axis, and tilting angles ( and ) of the V1V2 stem are illustrated. (B) Differences in
stem orientation between V1V2 domain complexes with MAb PG9 (magenta) and MAb 830A (green). Stem strands (highlighted in gray) are superimposed,
-barrels and their axes are indicated schematically as cylinders, and arrows highlight the change in barrel orientation. (C) A top view of V1V2(ZM53)-2J9C. The
trimeric scaffold (PDB accession number 2J9C) is shown in graywhile the threeV1V2s, based on theMAb 830A complexed structure, are shown in green, orange,
and gold. (D) A top view of V1V2(ZM109)-TTB. The typhoid toxin subunit B (TTB) pentamer is shown in gray while the V1V2 inserts, shown here as the
PG9-bound form, are colored. Note that the V1V2s are placed on top of the pentamer without any hindrance against each other.
Induction of Conformation-Speciﬁc V1V2 Ab Responses
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zations, a total of 100 g of the gp120 protein or an individual V1V2-
scaffold protein together with incomplete Freund adjuvant (IFA) was ad-
ministered intramuscularly (i.m.). Serum samples were collected prior to
immunization and 2 weeks after each immunization.
ELISA of V1V2 MAbs and antibodies in sera from immunized rab-
bits. ELISAs were performed using Immulon 4HBX plates coated with
antigens at a concentration of 1 g/ml and incubated overnight at 4°C.
After plates were blocked with PBS with 3% bovine serum albumin (BSA)
for 1.5 h, MAbs were added at a concentration of 10 g/ml. For serial
titration of test sera, ELISAs were performed with a starting dilution of
1:100, and individual preimmune sera were used as negative controls.
Following a 2-h incubation and threewasheswith PBS-Tween 20 (0.05%),
a 1:2,000 dilution of alkaline phosphatase-conjugated goat anti-rabbit IgG
(Southern Biotech) was added. After a 1-h incubation, plates were washed
three times with PBS-Tween 20. Alkaline phosphatase substrate (Sigma)
was added, and plates were read 30 min later at a wavelength of 405 nm.
The endpoint titer for each serumwas determined by the last dilution that
gave twice the signal of the background reading.
Competition antibody binding assay.A competition ELISAwas used
to determine epitope specificity, i.e., whether sera from vaccinated ani-
mals contained Abs recognizing epitopes similar to the well-characterized
Env-specific MAbs PG9, CH58, 697-D, and 830A. Dilutions of sera were
preincubated for 10 min at room temperature (RT) in wells of plates
(Immulon 4HBX) coated with antigens at a concentration of 1 g/ml,
followed by incubation for 2 h at RT with a biotinylated PG9, CH58,
697-D, or 830A. The concentration for each biotinylated MAb used was
predetermined in competition with its nonbiotinylated IgG. Plates were
washed with PBS containing 0.02% Tween 20 before incubation (1 h at
RT) with a streptavidin–horseradish peroxidase (HRP) reporter reagent
(product 21130; Pierce). Plates were read at a wavelength of 450 nm. A
reduction in signal reflects the presence of Abs in serum that competed
with labeled MAbs for binding to the plate-bound antigen.
Neutralization assays. For detection of neutralizing Abs (nAbs) in
rabbit immune sera, clade CMW965 (tier 1A) and ZM109 (tier 1B) pseu-
doviruses from the standard pseudovirus panels were used (44). A stan-
dard TZM.bl pseudovirus neutralization assay was performed (44, 45).
Briefly, serial dilutions of heat-inactivated serum were prepared starting
at a dilution of 1:10. The serum-pseudovirus mixtures were then incu-
batedwith the TZM.bl target cells, and luciferase activity wasmeasured 30
min or 24 h later. Prebleed sera were used as negative controls against each
pseudovirus, and all sera were also tested against a negative-control pseu-
dovirus carrying the envelope ofmurine leukemia virus. The percent neu-
tralization was calculated relative to the effect of the preimmune serum
from the same rabbit at the same dilution. All sera were assayed in dupli-
cate in at least two experiments against each virus. The 50%, 80%, and
90% inhibitory dose titers were calculated as the serum dilutions that
caused these percentages of reduction in relative luminescence units com-
pared to the level in the virus control wells.
RESULTS
Designandconstructionof structurallyunconstrainedandcon-
strained immunogens presenting V1V2 epitope types. We first
designed a couple of V1V2 immunogens mimicking the trimeric
V1V2 conformation in the stabilized BG505 SOSIP.664 gp140
context (46). Our initial design was based on the structures then
available: the low-resolution cryo-electron microscopy (EM)
structure of BG505 SOSIP/PG9 complex and a crystal structure of
a V1V2-1FD6 scaffold/PG9 complex (33, 47). The latter structure
demonstrated that V1V2 could be grafted onto -hairpins within
another protein. We searched the PDB for homotrimeric struc-
tures with exposed -hairpins and suitable spatial parameters for
scaffolding V1V2 (Fig. 1A and B). We identified that the trimer of
the MRG15 chromo-domain (PDB code 2F5K) has a -hairpin
that would accommodate V1V2 with the orientation present in
the SOSIP trimer. We designed a V1V2-scaffold immunogen
based on these structures, using the ZM53 sequence that has
relatively short V1 and V2 hypervariable loops. The chimeric
structure included the complete V1V2 domain with the termi-
nal Cys126 and Cys196 of ZM53 fused at the match points to
2F5K, excluding the turn residues in the original scaffold hairpin;
this immunogen is named V1V2(ZM53)-2F5K (Table 1). Mean-
while, we had determined a crystal structure of V1V2(ZM109)-
1FD6 in complex with a V2i MAb, 830A, and revealed that the
TABLE 1 Amino acid sequences of the rationally designed immunogens used in rabbit experiments H2 and H3
Name Amino acid sequence
V1V2(ZM53)-2F5K PKPKFQEGERVLCFHGPLLYEAKCVKVAILAACVTLNCSKLNNATDGEMKNCSFNATTELRDKKKQVYALFYKLDIVPLD
GRNNSSEYRLINCEETVKYFIHYSGWNKNWDEWVPESRVLKYVDTNLQKQRELQKANQEQYAEGKGLEVLFQGPG
HHHHHHHHSAWSHPQFEK
V1V2(ZM53)-2J9C GSMKKVEAIIRPEKLEIVKKALSDAGYVGMTVSEVKGRGVQGGIVERYCVTLNCSKLNNATDGEMKNCSFNATTELRDK
KKQVYALFYKLDIVPLDGRNNSSEYRLINCREYIVDLIPKVKIELVVKEEDVDNVIDIICENARTGDPGDGKIFVIPVER
VVRVRTKEEGKEALLEHGLEVLFQGPGHHHHHHHHSAWSHPQFEK
V1V2(ZM109)-TTB EWTGDNTNAYYSDEVISELHVGQIDTSPYFCIKTVKANGAGTPVVACAVSKQSIWAPSFKELLDQARYFYSTGQSVRIHV
QKNIWTYPLFVNTFSANALVGLSSCVKLTPLCVTLNCTSPAAHNESETRVKHCSFNITTDVKDRKQKVNATFYDLDIV
PLSSSDNSSNSSLYRLISCNTSTITQACFGPKLEVLFQGPGHHHHHHHHSAWSHPQFEK
V1V2(ZM109)-1FD6-Fc MTTFKLAACVTLNCTSPAAHNESETRVKHCSFNITTDVKDRKQKVNATFYDLDIVPLSSSDNSSNSSLYRLISCQTTTTEA
VDAATAAKVFKQYANDNGIDGEWTYDDATKTFTVTEGLEVLFQGASGGSKPTCPPPELLGGPSVFIFPPKPKDTLMIS
RTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLREQQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAP
IEKTISKARGQPLEPKVYTMGPPREELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYSKLS
VPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPGK
V1V2(1086)-Fc SLKPCVKLTPLCVTLNCTNVKGNESDTSEVMKNCSFKATTELKDKKHKVHALFYKLDVVPLNGNSSSSGEYRLINCNTSA
ITQACPKVSGASGGSKPTCPPPELLGGPSVFIFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARP
PLREQQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPPREELSSRSVSLTCMI
NGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYSKLSVPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPGK
V1V2(ZM109)-Fc SLKPCVKLTPLCVTLNCTSPAAHNESETRVKHCSFNITTDVKDRKQKVNATFYDLDIVPLSSSDNSSNSSLYRLISCNTSTIT
QACPKVSGASGGSKPTCPPPELLGGPSVFIFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPL
REQQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAPIEKTISKARGQPLEPKVYTMGPPREELSSRSVSLTCMIN
GFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYSKLSVPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPGK
Jiang et al.
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FIG 2 Antigenicity tests of V1V2 immunogens. (A) Electrophoresis of purified immunogens. Isolated molecules were resolved by SDS-PAGE and stained with
Coomassie blue. Lanes 1 to 8 are gp120(ZM109), V1V2(1086)-Fc, V1V2(ZM53)-2J9C, V1V2(ZM109)-1FD6-Fc, V1V2(ZM109)-1FD6, V1V2(ZM53)-2F5K,
V1V2(ZM109)-Fc, and V1V2(ZM109)-TTB, respectively. Molecular weight (MW) standards (in thousands) are marked on the side. (B to E) Binding of V1V2
immunogens to V2qMAb PG9, V2pMAb CH58, and V2i MAbs 697-D and 830A analyzed by ELISA. Note that in the top two panels, immunogens that bound
well to the V2q MAb PG9 bound poorly to the V2p MAb CH58, and vice versa. (F and G) Titration of MAbs PG9 and CH58 to V1V2(ZM109)-1FD6 and
V1V2(ZM109)-Fc. Note that although these two V1V2-scaffold antigens have the same V1V2 sequence, the structurally constrained V1V2(ZM109)-1FD6 binds
only PG9 while the unconstrained V1V2(ZM109)-Fc binds only CH58. Thus, the V2q epitope type (recognized by PG9) and the V2p epitope type (recognized
by CH58) could be selectively presented by the structurally constrained and unconstrained V1V2 immunogens, respectively. OD, optical density.
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V1V2 domain can adopt a five-strand -barrel conformation
(6) that is distinct from the four-strand structure observed in
complexes with MAbs PG9 and PG16 (33, 34). Remarkably,
this change is accompanied by the bending of the V1V2 stem
-strands so that the tilt of the -barrel with respect to the stem
strands is different (Fig. 1B). Search of the PDB showed that the
structure of the GlnK1 protein from Methanococcus jannaschii
(PDB code 2J9C) would be suitable for scaffolding this V1V2 con-
formation. Thus, we have constructed another trimeric V1V2
scaffold, V1V2(ZM53)-2J9C (Table 1 and Fig. 1C). We produced
these trimeric V1V2-scaffold proteins in the HEK293S GnTI/
cells that produce only high-mannose glycans, which are more
homogeneous than complex glycans (43) (Fig. 2A). Antigenicity
tests showed that both V1V2(ZM53)-2F5K and V1V2(ZM53)-
2J9C could bind PG9 as well as 697-D and 830A; thus, they harbor
V2q and V2i epitopes (Fig. 2B to E and Table 2).
As noted above, trimeric arrangement of V1V2 domains in
V1V2(ZM53)-2F5K and V1V2(ZM53)-2J9C constructs was based
on approximate geometry deduced from low-resolution electron
microscopy structures. After the constructs were designed and
entered experimental evaluation, high-resolution X-ray struc-
tures of SOSIP trimers became available (5, 7). We compared
configurations of V1V2 domains in our constructmodels with the
SOSIP structure (PDB accession number 4TVP). We found that
the positions of the center of mass of the V1V2 domains deviated
by only 1.9Å and 1.6 Å for 2F5K- and 2J9C-based constructs,
respectively. The V1V2 domain was also rotated by 18° in the
2F5K-based construct, while in the 2J9C-based construct, the ro-
tation angle reached 96°. Thus, the 2F5K-based construct design is
predicted to achieve a V1V2 domain configuration that is signifi-
cantly closer to the native-like closed spike trimer state. It should
be noted that the -strands connecting the V1V2 domains to the
scaffold are likely to be substantially flexible, and therefore do-
main orientations are expected to sample a range of positions
around the modeled ones.
The scaffold molecule V1V2(ZM109)-1FD6 used in crystalli-
zation with PG9 and PG16 (33) naturally carries the V2q type of
epitopes. However, the molecule is rather small (25 kDa with
glycans) and was not very immunogenic in rabbits (data not
shown). We therefore tried to improve its immunogenicity by
attaching at its C terminus the rabbit Fc fragment. In the anti-
genicity test, this bivalent immunogen, V1V2(ZM109)-1FD6-Fc
(Table 1), was able to bind PG9 aswell as 697-D and 830A (Fig. 2B,
D, and E); thus this immunogen harbors the V2q andV2i epitopes
(Table 2).
We also constructed two immunogens based on pentameric
bacterial toxin B subunits. We had previously tested cholera toxin
B subunit (CTB)-based immunogens carrying HIV-1 V3 epitopes
and showed that they were highly immunogenic and elicited
cross-clade neutralizing Ab responses in rabbits (48–50). To test
CTB’s effects on V1V2 immunogens, we chemically conjugated
the structurally constrained V1V2(ZM109)-1FD6 with the CTB
and showed that it preserved the V2q and V2i epitopes in the
V1V2 scaffold (Fig. 2B,D, andE).We also created aV1V2-typhoid
toxin B subunit (TTB) fusion protein V1V2(ZM109)-TTB (Table
1), taking advantage of the fact that TTB harbors a disulfide bond
near its C terminus, which is a naturally suitable place for grafting
the disulfide-linked V1V2 domain (PDB accession number 4K6L)
(Fig. 1D). Computer modeling showed that the pentameric TTB
can host five copies of V1V2 without any structural hindrances
(Fig. 1D). Interestingly, V1V2(ZM109)-TTBharbors the structur-
ally constrainedV2q andV2i epitopes (Fig. 2B,D, and E) although
its pentameric form does not resemble in any way that of V1V2 in
the gp120 trimer.
To construct structurally unconstrained V1V2 molecules,
we fused the V1V2 domains of clade C strain 1086 or ZM109 to
the rabbit Fc (Table 1). Since only the C terminus of the V1V2
(after theV1V2 disulfide bond) is linked to the flexibleN terminus
of Fc, there are no constraints imposed on the V1V2 -hairpin
stem. Indeed, antigenicity tests showed that V1V2(1086)-Fc and
V1V2(ZM109)-Fc were recognized by the V2p MAb CH58 but
not by the V2q MAb PG9 (Fig. 2B, C, F, and G); thus, these un-
constrained V1V2s harbor the V2p epitopes (Table 2).
These data describe a panel of immunogens that can present
theV2q, V2p, andV2i epitopes (Tables 1 and 2). TheV2q epitopes
can be presented by the immunogens with structurally con-
strained V1V2s, while the V2p epitopes can be presented by the
immunogens with unconstrained V1V2s. In contrast, V2i
epitopes can be presented by immunogens with either con-
strained or unconstrained V1V2s.
DNAprime-proteinboost regimenusing rationallydesigned
immunogens elicited strong Ab responses targeting gp120 V1V2.
To test the immunogenicity of our immunogens, we carried out two
rabbit experiments, H2 and H3 (Table 3). In rabbit experiment
H2, we tested six immunogens, including the gp120(ZM109)
monomer (rabbit group H2.1), the trimeric, structurally con-
strained V1V2(ZM53)-2J9C (H2.2), the structurally uncon-
strained V1V2(1086)-Fc (H2.3), the structurally constrained
V1V2(ZM109)-1FD6-Fc (H2.4), the pentameric, structurally
constrained toxin subunit B-based V1V2(ZM109)-TTB (H2.5), and
the structurally constrained cross-linked construct V1V2(ZM109)-
1FD6CTB (H2.6). In this experiment, we used a DNA prime-
protein boost regimen (with three consecutive DNA primes fol-
lowed by three protein boosts) that we had used previously in
successfully inducing Ab responses in rabbits (49–51). The DNA
priming immunogen was a plasmid DNA encoding monomeric
gp120(ZM109). In experiment H3 (Table 3), we tested another
trimeric immunogen V1V2(ZM53)-2F5K (groupH3.1), repeated
the structurally constrained V1V2(ZM109)-1FD6-Fc (H3.2) in
comparison with an immunogen with the same V1V2 sequence
but structurally unconstrained V1V2(ZM109)-Fc (H3.3). In ad-
dition, we tested a new regimen in which animals were primed
with theDNA aswell as the protein (Table 3) (52), usingDNA and
TABLE 2 Types of epitopes carried by the immunogens and antigens
used in this studya
Antigen
V2q
(reactive
with PG9)
V2i (reactive
with 697-D
and/or 830A)
V2p
(reactive
with CH58)
V1V2(ZM53)-2J9C   
V1V2(1086)-Fc   
V1V2(ZM109)-1FD6-Fc   
V1V2(ZM109)-TTB   
V1V2(ZM109)-1FD6CTB   
V1V2(ZM53)-2F5K   
V1V2(ZM109)-Fc   
V1V2(ZM109)-1FD6   
V1V2(1086)-tags   
a and, presence and absence of the epitope type, respectively.
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two protein immunogens we had tested in the rabbit H2 experi-
ment, V1V2(ZM53)-2J9C (H3.4) and V1V2(ZM109)-TTB (H3.5).
The priming was then followed by two protein boosts with the
same protein immunogens.
Sera from the animals for both H2 and H3 experiments dis-
played strong and distinct Ab responses to our immunogens as
assessed by ELISA. To detect the Ab responses, we used three
V1V2 antigen probes, including the structurally constrained
V1V2(ZM109)-1FD6 (Fig. 3A) and V1V2(CAP45)-1FD6 (Fig.
3B), which had been used in complex with PG9 and PG16 for
crystallization (33), as well as the unconstrained V1V2(1086)-tags
(Fig. 3C) (23). All three antigens used in ELISAs carried V1V2
regions derived from clade C viruses, but their sequences differed.
The Ab responses clearly separated into two distinct groups based
on their ELISA binding to the structurally constrained probes
(Fig. 3A and B) and the unconstrained probe (Fig. 3C). Thus, the
structurally constrained V1V2 immunogens induced strong Ab re-
sponses reactive with the structurally constrained antigen probes
V1V2(ZM109)-1FD6 and V1V2(CAP45)-1FD6, while the uncon-
strained immunogens, V1V2(1086)-Fc andV1V2(ZM109)-Fc, were
the only immunogens that induced Abs recognized, albeit more
weakly, by the unconstrained antigen V1V2(1086)-tags. Although
Abs induced by gp120(ZM109) could recognize V1V2(ZM109)-
1FD6, their binding was reduced against the heterologous
V1V2(CAP45)-1FD6 probe, suggesting that gp120(ZM109) in-
duced more sequence-specific Ab responses. Interestingly, in ex-
periment H3, the structurally unconstrained V1V2(ZM109)-Fc
was able to induce strong Ab responses against the constrained
scaffolded V1V2 probes, which is substantially different from the
results of the V1V2(1086)-Fc in experiment H2 (Fig. 3A and B).
This result suggested that the amino acid sequence could influence
the structural conformation in the construct. However, the
epitope specificity of the Ab responses induced by the structurally
unconstrained V1V2(ZM109)-Fc was different from that of the
TABLE 3 The design of rabbit studies H2 and H3
Study group No. of rabbits Rabbit no. Primea Boostb
H2.1 3 H2.1.1–H2.1.3 gp120.ZM109 DNA gp120(ZM109)
H2.2 4 H2.2.1– H2.2.4 V1V2(ZM53)-2J9C
H2.3 4 H2.3.1– H2.3.4 V1V2(1086)-Fc
H2.4 5 H2.4.1– H2.4.5 V1V2(ZM109)-1FD6-Fc
H2.5 5 H2.5.1– H2.5.5 V1V2(ZM109)-TTB
H2.6 4 H2.6.1– H2.6.4 V1V2(ZM109)-1FD6CTB
H3.1 5 H3.1.1– H3.1.5 gp120.ZM109 DNA V1V2(ZM53)-2F5K
H3.2 5 H3.2.1– H3.2.5 V1V2(ZM109)-1FD6-Fc
H3.3 5 H3.3.1– H3.3.5 V1V2(ZM109)-Fc
H3.4 5 H3.4.1– H3.4.5 gp120.ZM109 DNA V1V2(ZM53)-2J9C V1V2(ZM53)-2J9C
H3.5 5c H3.5.1– H3.5.3, H3.5.5 gp120.ZM109 DNA V1V2(ZM109)-TTB V1V2(ZM109)-TTB
a For the priming immunizations, the codon-optimized gp120.ZM109 DNA vaccine (36 g/dose, 1 g/shot) was delivered by gene gun at weeks 0, 2 and 4, in all groups. In groups
H3.4 and H3.5, the rabbits also received V1V2-scaffold protein boosts (100 g/dose) formulated with IFA adjuvant by the intramuscular (i.m.) route at the same time of DNA
immunization, as indicated.
b For the boosting immunizations, the individual V1V2 scaffold protein (100 g/dose) formulated with IFA adjuvant was administered by the i.m. route.
c One animal (animal H3.5.4) had to be terminated early due to health issues.
FIG3 Endpoint titers of the rabbit Ab responses of the V1V2 immunogens. Endpoint binding titers of sera for all theH2 andH3 rabbits weremeasured by ELISA
against the structurally constrained V1V2(ZM109)-1FD6 (A) and V1V2(CAP45)-1FD6 (B) and the unconstrained V1V2(1086)-tags (C). Each point represents
the average titer calculated from duplicate samples of individual rabbits. The data points of sera from animals immunized with structurally unconstrained
immunogens are marked by crosses while that with the constrained immunogens are marked by open circles. The vertical dashed line in each panel separates the
H2 and H3 animal groups. The statistical difference between the Ab responses in H2 induced by the structurally constrained and unconstrained immunogens
measured against V1V2(ZM109)-1FD6 andV1V2(CAP45)-1FD6 is highly significant (P	 0.0001). The statistical differences between the Ab responses induced
by the structurally constrained V1V2(ZM109)-1FD6-Fc and the unconstrained V1V2(ZM109)-Fc are indicated. ns, not significant; *, P	 0.05.
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constrained V1V2(ZM109)-1FD6-Fc, as revealed by the competi-
tion assay (see below).
V1V2-scaffold immunogens induce distinct conformation-
specific V1V2-directed Ab responses. To gain additional under-
standing of the conformational specificities of the Ab responses
induced by V1V2-scaffold immunogens in rabbits, we performed
an Ab competition assay for the rabbit immune sera with the V2q
MAb PG9, V2pMAb CH58, and V2i MAbs 697-D and 830A (Fig.
4 and 5). In this assay, we coated the plates with antigen probes
that carry different epitope types and competed the rabbit sera
with biotinylated MAbs. These V1V2 MAbs were used first to
compete against each other (Fig. 4). The data showed that only the
two V2i MAbs, 697-D and 830A, competed against each other,
further illustrating the distinctness of the three types of V1V2
epitopes. Rabbit sera taken 2 weeks after the last protein boost
were then used to compete against V1V2 MAbs (Fig. 5). Serum
from individual rabbits of each group was tested separately, and
only the curve of a representative rabbit of the groups that dem-
onstrated clear competition is shown in Fig. 5. Sera from rabbit
groups immunized by the structurally constrained immunogens
V1V2(ZM53)-2J9C (Fig. 5A, represented by rabbit numbers
H2.2.1 and H3.4.1), V1V2(ZM109)-TTB (Fig. 5A, H2.5.1), and
V1V2(ZM109)-1FD6-Fc (Fig. 5A, H2.4.1) showed pronounced
competition against PG9 for the binding of V1V2(ZM109)-1FD6,
suggesting that these immunogens inducedAbswhose epitopesover-
lap, and are conformationally similar to, theV2q epitopes. Therewas
variation between animals: serum from rabbit H2.4.3 did not show
strong competition with PG9, unlike that of rabbit H2.4.1, as
shown in Fig. 5, and of the other three rabbits in the group. On
the other hand, sera from rabbits of the group immunized with
V1V2(1086)-Fc (H2.3.2) competed well with the V2pMAbCH58
for binding to V1V2(1086)-tags. Interestingly, sera from rabbits
immunized with the trimeric immunogens V1V2(M53)-2J9C
(Fig. 5B, H2.2.1 and H3.4.1) and V1V2(M53)-2F5K (Fig. 5B,
H3.1.1) could also competewithCH58withmodest strength, sug-
gesting that these constructs can also sample the helical confor-
FIG 4 Competition of V1V2 MAbs against each other. (A) An illustration of the competition assay setup. (B) To establish the baseline, we first competed each
V1V2MAb against itself. Shown here is V2qMAb PG9 competed with itself for structurally constrained antigen V1V2(ZM109)-1FD6 coated on the plate using
PBS as a negative control. (C to F) Competition of V2qMAb PG9, V2i MAbs 697-D and 830A, and V2pMAb CH58 by biotinylated MAbs PG9 (C), 697-D (E),
and 830A (F) for V1V2(ZM109)-1FD6 coated on the plates. Panel D shows competition of the sameMAbs by biotinylated V2pMAbCH58 for V1V2(1086)-tags.
Note that PG9 and CH58 each only competed with itself (C and D), while V2i MAb 830A and 697-D competed with each other. Although CH58 does not bind
V1V2(ZM109)-1FD6 and PG9 does not bind V1V2(1086)-tags, they were included for references.
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mations. In contrast, no serum gave very strong competition
against the V2i MAbs 697-D and 830A (data not shown). Figures
5C and D illustrate the difference in the Abs induced by the two
immunogens V1V2(ZM109)-1FD6-Fc and V1V2(ZM109)-Fc
that have the same V1V2 sequence. The structurally constrained
V1V2(ZM109)-1FD6-Fc clearly induced Abs that could compete
strongly with PG9, while the Abs induced by the unconstrained
V1V2(ZM109)-Fc could compete very little (Fig. 5C). Interest-
ingly V1V2(ZM109)-Fc (Fig. 5D) did not induce Abs that could
compete strongly with CH58, unlike Abs induced by V1V2
(1086)-Fc (Fig. 5B, H2.3.2).
V1V2 immunogen-induced antibody neutralization.We as-
sessed the neutralizing activity of all immune sera from experi-
ment H3 using the TZM.bl assay under conditions in which the
virus and sera were incubated together for either 30 min or 24
h prior to addition to cells, as per previous studies (53); the
pseudoviruses of strains MW965 and ZM109 were used (Table
4 and Fig. 6, respectively). Although strains MW965 (tier 1A)
and ZM109 (tier 1B) are neutralization-sensitive viruses, they
could not be neutralized by the RV144 V2p MAb CH58 (data
not shown). Sera drawn 2weeks after the last boost fromalmost all
animals achieved neutralization of MW965 in the 30-min assay
while all sera achieved 50%neutralization in the 24-h assay (Table 4).
In assays using the tier 1B strainZM109 (Fig. 6) in the 24-h assay, sera
from four of the five groups in experiment H3, boosted with the
structurally constrained V1V2(ZM109)-1FD6-Fc or V1V2(ZM53)-
2J9C, gave 50% neutralization (values above the dashed line in
Fig. 6B). Since the V1V2 sequence of V1V2(ZM53)-2J9C used in
immunizing group H3.4 is different from that of ZM109, the im-
mune sera of this group achieved heterologous neutralization in
the 24-h assay. Sera from two animals immunized with another
trimeric protein, V1V2(ZM53)-2F5K, also achieved heterologous
neutralization of ZM109 in the 24-h assay.
DISCUSSION
Data from the RV144 phase III vaccine trial, the only HIV/AIDS
vaccine trial that demonstrated modest 31.2% efficacy, suggested
that the V1V2 region of HIV-1 gp120 is a key vaccine target (31,
35–37). Clearly, a more efficacious vaccine is needed. Based on
data ofMAbs isolated from an RV144 vaccinee, we know that V2p
Abs were induced (23). However, the absence of strong neutraliz-
ing activity in RV144 sera suggests that V2q Abs were not induced
(38). Which, if any, of these types of V2 Abs were directly respon-
sible for the reduced rate of infection is not known at this point.
However, our classification of V1V2 epitopes into three distinct
types, i.e., the V2q, V2p, and V2i types, provided a conceptual
starting point for designing immunogens that can focus the im-
mune responses to each of these types (26, 27).
Structural studies of V1V2 and theMAbs that bind to the V2p/
V2q epitope region have illuminated the structural complexity of
this region, indicating that it can assume at least two conforma-
tions: one that is recognized by V2p MAbs in which the strand C
region assumes a helical conformation appeared to be present in
molecules inwhichV1V2 is not constrained, such as V1V2(1086)-
tags (Fig. 2C) (23), and one that is recognized by V2q MAbs in
which the region is present as a -strand, as in the case of mole-
cules where V1V2 is constrained, such as V1V2(ZM109)-1FD6
and V1V2(CAP45)-1FD6 (33, 34). However, the V2i epitopes
do not overlap V2p and V2q epitopes (Fig. 4) (6), and V2i Abs
can recognize V1V2 constructs harboring both conformations
(Table 2).
We have shown here that we could design immunogens targeting
the helical V2p and -stranded V2q epitope types. In particular, the
structurally constrained V1V2-scaffold proteins, such as the trimeric
V1V2(ZM53)-2J9C and V1V2(ZM53)-2F5K and the pentameric
V1V2(ZM109)-TTB, can harbor the -stranded conformation
FIG5 Competition of rabbit sera against V1V2MAbs. (A andB)Results of rabbit sera competed against V2qMAbPG9 andV2pMAbCH58. As references, black
curves from data of prebleeds and competition against the same MAb are included. (C and D) Competition against V2q MAb PG9 and V2p MAb CH58, as
indicated, by sera from rabbits immunized with either structurally constrained V1V2(ZM109)-1FD6-Fc or the unconstrained V1V2(ZM109)-Fc.
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while the simple Fc fusion forms of V1V2 carry the helical confor-
mation of the epitopes. These epitope scaffold immunogens can
induce distinct Ab responses in rabbits, i.e., the unconstrained
immunogens induced Abs that reacted preferentially with the un-
constrained antigen V1V2(1086)-tags, while the constrained im-
munogens induced Abs that reacted preferentially with the con-
strained antigens V1V2(ZM109)-1FD6 and V1V2(CAP45)-1FD6
(Fig. 3). Moreover, the Abs induced by the immunogens carrying
the V2q epitopes could compete with the V2q MAbs PG9 while
those induced by the immunogens carrying the V2p epitopes
could compete with the V2p MAbs CH58 (Fig. 5). In addition,
sera of several rabbits could neutralize the tier 1A virus MW965,
which is heterologous to the immunizing strains, and the tier 1B
virus ZM109 in the 24-h incubation assay (Table 4 and Fig. 6),
representing a significant improvement from the V1V2 Abs in-
duced by the RV144 vaccines.
These rabbit experiments are among the first to demonstrate
that the immune response can be focused on the V1V2 region
(54). The cross-reactivity of human V1V2 Abs has long been es-
tablished although this region has the most sequence and length
diversity in the HIV-1 Env (22). This immunologic cross-reactiv-
ity in the face of variable amino acid sequences as well as insertions
and deletions can be explained on the basis of the structural data
that have emerged in the last few years. Thus, the -barrel struc-
ture that has been described for V1V2 likely forms a conserved
functional module (6), which not only explains the conserved
antigenic structure that allows antigenic cross-reactivity but also
allows the transplantation of the whole domain into scaffolds by
rational structural designs.
The Ab response to V1V2 in HIV-infected individuals is less
robust than that to V3 or the CD4-binding site (22, 55, 56), and
V1V2Ab responses were of amuch smallermagnitude in previous
vaccine studies than in the RV144 study, suggesting that despite its
prominent location on the Env spike, V1V2 is not an immuno-
dominant epitope region. We have shown in the data presented
here that presenting V1V2 in a multivalent scaffold overcomes its
relatively poor immunogenicity as well as inducing cross-reactive
Abs. To induce even higher levels of Abs, these constructs can be
readily modified to form nanoparticles, such as virus-like parti-
cles, which will present the V1V2 domain at even higher valences
capable of improved interaction with B cell receptors. These stud-
ies are currently ongoing.
Our data further demonstrate that one can selectively focus the
Ab response on particular conformations of an epitope region.
The helical conformation of the V2p epitope is likely a means of
masking the vulnerable -strand conformation of the same re-
gion. Side chains of a helix point away from the helix axis, and
helix-specific Abs are generally side chain specific. From the point
of view of the virus, helix-specific Abs would be preferential since
virus escape by mutation from such Abs would be relatively sim-
ple. Escape from complex conformational epitopes, such as those
targeted by V2q and V2i Abs, would be more complicated. The
distinct characteristics of the Abs induced by structurally con-
strained immunogens and those induced by the unconstrained
ones (Fig. 3 and 5) suggest that the rabbit immune system re-
sponded differently against the two types of immunogens.
Data presented here suggest that our immunogens could serve
as prototype vaccine candidates targeting the V1V2. While novel
in the current iterations, improvements could induce Abs that are
more V2q-like. For example, trimer-specific MAbs like PGT145
were shown to bind close to the axis of the Env trimer, and their
epitopes are likely V1V2 specific (57); but our two trimeric im-
munogens were not recognized by PGT145 (data not shown).
Since our trimeric scaffolds are recognized by PG9, the C strand of
the V1V2 apex is likely correctly formed; thus, their orientation
toward the trimer axis may deviate from that of the epitope of
PGT145. Such orientation can be adjusted at the V1V2-scaffold
junction, and computational modeling in combination with
antigenicity testing will be able to identify improved constructs.
Furthermore, the current V1V2 constructs, even the structurally
constrained ones, are likely to be able to sample different confor-
mations so that the trimeric immunogens could induce Abs that
compete with the V2p MAb CH58. Additional stabilizations
may reduce such dynamic sampling between conformations.
Finally, the different functional activities of V1V2(ZM109)-Fc
and V1V2(1086)-Fc suggested that the amino acid sequence of
TABLE 4 The inhibitory dose titers of the H3 rabbit sera against
MW965 in a 30-min and a 24-h TZM.bl neutralization assaya
MW965 (clade C)
Serum 
#
Rabbit #
30 min 24h
ID50 ID80 ID90 ID50 ID80 ID90
1 H3.1.1 264 60 <10 1766 806 663
2 H3.1.2 40 15 <10 1633 459 316
3 H3.1.3 10 <10 <10 108 19 13
4 H3.1.4 56 22 <10 2575 613 287
5 H3.1.5 61 40 35 3907 1454 803
6 H3.2.1 29 <10 <10 1006 298 187
7 H3.2.2 14 <10 <10 668 98 61
8 H3.2.3 11 <10 <10 1020 62 30
9 H3.2.4 12 <10 <10 1119 167 78
10 H3.2.5 <10 <10 <10 24 16 13
11 H3.3.1 12 10 <10 377 81 55
12 H3.3.2 36 25 <10 1378 272 151
13 H3.3.3 13 <10 <10 513 141 101
14 H3.3.4 12 <10 <10 191 62 37
15 H3.3.5 16 <10 <10 792 190 132
16 H3.4.1 <10 <10 <10 136 65 41
17 H3.4.2 11 <10 <10 357 160 102
18 H3.4.3 39 <10 <10 845 287 159
19 H3.4.4 11 <10 <10 251 119 79
20 H3.4.5 10 <10 <10 216 107 73
21 H3.5.1 11 <10 <10 354 134 104
22 H3.5.2 12 <10 <10 392 98 64
23 H3.5.3 17 <10 <10 417 115 75
25 H3.5.5 25 14 10 1064 426 295
a ID50, ID80, and ID90 are the 50%, 80%, and 90% inhibitory doses, respectively.
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V1V2 can also play a role in their function. Therefore, sequence
selection is another area for potential improvement, with atten-
tion paid to both amino acid sequence and variable loop lengths
(58). We anticipate that a combination of sequence selection,
structure-based design, and formulation as highly multivalent
constructs will likely lead to V1V2 immunogens with superior
ability to focus the Ab response on this site of vulnerability and
with increased immunogenicity.
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